Related Experiment Video
Updated: Mar 18, 2026
10:44
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
11.3K
Current and emerging treatment of multiple sclerosis
Felecia M Hart, Jacquelyn Bainbridge1
1Jacci.Bainbridge@ucdenver.edu.
The American Journal of Managed Care
|June 30, 2016
Summary
Multiple sclerosis (MS) treatments include managing relapses, slowing progression with disease-modifying therapies (DMTs), and symptom relief. Optimal DMT selection requires balancing efficacy and rare adverse events.
Area of Science:
- Neurology
- Immunology
Background:
- Multiple sclerosis (MS) management is complex, involving treatments for exacerbations, disease progression, and symptoms.
- Disease-modifying therapies (DMTs) aim to reduce relapses and slow lesion accumulation.
- Early intervention with DMTs is recommended to prevent long-term disability.
Purpose of the Study:
- To provide an overview of current and emerging treatments for multiple sclerosis.
- To emphasize disease-modifying therapies (DMTs) in MS management.
- To highlight the need for careful risk-benefit assessment of DMTs.
Main Methods:
- Review of existing literature on multiple sclerosis treatments.
- Focus on disease-modifying therapies (DMTs) and their mechanisms.
- Analysis of comparative efficacy and safety data for DMTs.
Main Results:
- Numerous DMTs are available, offering options to reduce relapse frequency and severity.
- Newer DMTs show promise but carry risks of rare, serious adverse events.
- There is a recognized gap in comparative efficacy data and clinical guidelines for DMT selection.
Conclusions:
- Optimal selection of DMTs for MS requires careful consideration of individual patient profiles and risk-benefit analysis.
- Further research is needed to provide comparative efficacy data to guide clinical practice.
- Balancing treatment benefits against potential risks is crucial for effective MS management.
More Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:30Electroconvulsive Therapy
1.8K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.8K
01:28Drug Therapy
376
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
376
01:29Microorganisms in Medicine and Therapeutics
1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K